PHA Accreditation Program Assures Access to Specialized Care for Thousands With Often-Misdiagnosed Deadly Lung Disease

Silver Spring, MD (February 15, 2018) – A national accreditation program launched by the Pulmonary Hypertension Association (PHA) assures that more than 12,000 people with a life-threatening lung disease are getting care from clinicians who specialize in their often-misdiagnosed condition. Pulmonary hypertension (PH), also known as high blood pressure of the lungs, affects adults

2018-02-16T16:07:20+00:00 February 16th, 2018|

Adding Immunoadsorption to Current Treatment for People With IPAH

Study looks at a theory that adding immunoadsorption, or the process of filtering out antibodies from the blood, in addition to other PH therapies may help improve outcomes for people with idiopathic pulmonary arterial hypertension. by Phyllis Hanlon, Contributing Writer   People with idiopathic pulmonary arterial hypertension (IPAH), a type of WHO Group 1 PH (PAH,

2018-02-15T18:13:05+00:00 February 15th, 2018|

An Overview of Pulmonary Arterial Hypertension (PAH) and Lupus

WHO Group 1 PH (PAH, pulmonary arterial hypertension) can appear by itself of be associated with other medical conditions including connective tissue diseases (CTD), such as systemic lupus erythematosus (SLE). Although CTD-associated PAH is very common in people who have PAH, PAH is extremely uncommon among the many people with SLE. Because of this, a

2018-02-09T03:24:39+00:00 February 9th, 2018|

Researchers: Collect Data at Unique Opportunity in PH Field

Investigator Applications are now being accepted for the Research Room at PHA’s 2018 International PH Conference and Scientific Sessions. The Research Room helps researchers further their studies by providing the opportunity for collection of data, including phenotypic information and biological specimens, from the largest gathering of pulmonary hypertension patients in the world. Impact the field

2018-02-01T17:37:14+00:00 February 1st, 2018|

Treating Pulmonary Hypertension Associated With Connective Tissue Disease

by Phyllis Hanlon, Contributing Writer  WHO Group 1 PH (PAH, pulmonary arterial hypertension) is a progressive and chronic disease. There currently is no cure. In PAH, the arteries in the lungs become narrow, thickened or stiff, which causes high blood pressure in the lungs. The disease can present in several forms, one of which

2018-01-31T22:16:23+00:00 January 31st, 2018|

Webinar for Medical Professionals CTEPH: Finding, Treating and Future Directions

Friday, February 9th, 2018, 3:00 p.m. ET Josanna M. Rodriguez-Lopez, M.D., Massachusetts General Hospital This webinar will focus on WHO Group 4 pulmonary hypertension (PH), chronic thromboembolic pulmonary hypertension (CTEPH), and will include information about what makes CTEPH unique from other types of PH and why it is important to rule out CTEPH in

2018-02-09T03:44:57+00:00 January 31st, 2018|

Ethnicity and PAH: Presentation, Treatment Options and Outcomes

Studies indicate differences among racial and ethnic groups in type of pulmonary arterial hypertension (PAH) diagnosed, treatments used and outcomes. by Phyllis Hanlon, Contributing Writer  Some medical researchers have begun studying differences in certain diseases among racial and ethnic groups to create better treatment plans for different health conditions and move toward more targeted

2018-01-25T17:30:33+00:00 January 25th, 2018|

Research Looks at Use of Health Care Resources and Costs of Care for People With Pulmonary Arterial Hypertension

Study Looks at Importance of Documenting Functional Class for PAH Patients by Phyllis Hanlon, Contributing Writer People with WHO Group 1 PH (PAH, pulmonary arterial hypertension) often experience a delay before a definitive diagnosis is made. After diagnosis is confirmed, doctors look at how severe the disease is using a classification system – either

2018-01-18T16:52:57+00:00 January 18th, 2018|

Attention PH Researchers: Collect Data at Rare Opportunity in PH Field

Investigator Applications are now being accepted for the Research Room at PHA’s 2018 International PH Conference and Scientific Sessions. The Research Room is dedicated to helping researchers further their studies by allowing for the collection of data, including phenotypic information and biological specimens. This event gives researchers the rare opportunity to collect data from the

2018-01-17T18:11:21+00:00 January 17th, 2018|

Call for Abstracts for PHA’s 2018 Scientific Sessions Committee and CTEPH Grants Opportunity

Call for Abstracts Do you have an abstract from CHEST or ACC? The Pulmonary Hypertension Association’s 2018 Scientific Sessions Committee is accepting encore and new abstract and case study submissions for PHA’s 2018 International PH Conference and Scientific Sessions to be held June 29-July 1, 2018, in Orlando, Florida. Abstract submissions are invited in the areas of basic

2017-12-14T17:21:32+00:00 December 14th, 2017|